A structured trial of risperidone for the treatment of agitation in dementia

American Journal of Geriatric Psychiatry

Volumn 6, Issue 2, 1998, Pages 127-135

  Lavretsky, Helen ^a   Sultzer, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

AGED; AGGRESSION; AGITATION; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE;

EID: 0031925402     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199805000-00006     Document Type: Article

References (57)

1. Devanand DP, Brockington CD, Moody BJ, et al: Behavioral syndromes in Alzheimer's disease. Int Psychogeriatr 1992; 4(suppl 12):161-184
2. Sultzer DL, Levin HS, Mahler ME, et al: Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. J Am Geriatr Soc 1992; 40:549-555
3. Cummings JL, Victoroff JI: Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1990; 3:140-158
4. Murray MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord 1994;8(suppl 3):54-60
5. Rabins PV: Noncognitive symptoms in Alzheimer's disease: definitions, treatments, and possible etiologies, in Alzheimer's Disease. Edited by Terry RD, Katzman R, Bick KL. New York, Raven, 1994, pp 419-429
6. Lake JT, Grossberg GT: Management of psychosis, agitation, and other behavioral problems in Alzheimer's disease. Psychiatr Ann 1996; 26:274-279
7. Cooper JK: Drug treatment of Alzheimer's disease. Arch Intern Med 1991; 151:245-249
8. Schneider LS, Pollock VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563
9. Jeste DV, Caligiuri MP, Paulsen JS, et al: Risk of tardive diskinesia in older patients: a prospective longitudinal study of 260 outpatients. Arch Gen Psychiatry 1995; 52:756-765
10. Devanand DP, Levy SR: Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8(suppl 1):S18-S27
11. Leysen JE, Janssen PMF, Megens AAHP, et al: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism: receptor occupancy profile and pharmacologic activity. J Clin Psychiatry 1994; 55(suppl 5):5-12
12. Ereshefsky L, Lacombe S: Pharmacological profile of risperidone. Can J Psychiatry 1993; 38(suppl 3):S80-S88
13. Mertens C: Long-term treatment of chronic schizophrenic patients with risperidone. Clin Neuropharmacol 1991; 14:44-48
14. Czobor P, Vlavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15:243-249
15. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
16. Berman I, Merson A, Pavlov-Rachov J, et al: Risperidone in elderly schizophrenic patients: an open-label trial. Am J Geriatr Psychiatry 1996; 4:173-179
17. Wasserman TW: Effects of risperidone in patients with developmental disability. Poster presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May, 1996
18. McDougle CJ, Brodkin RS, Young, PP, et al: Risperidone for aggression in autism or pervasive developmental disability. J Child Adolesc Psychopharmacol 1995; 5:273-282
19. Miczek KA, Weerts E, Haney M, et al: Neurobiological mechanisms controlling aggression: preclinical developments for pharmacotherapeutic interventions. Neurosci Biobehav Rev 1994: 18:97-100
20. Lee H, Cooney JM, Lawlor BA: The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994; 9:414-417
21. Allen RL, Walker Z, Dath PJ, et al: Risperidone for psychotic and behavioral symptoms in Lewy body dementia (letter). Lancet 1995; 346:185
22. Aronson SM, Lingam V, Hasanat KA: Risperidone in geropsychiatry: review of early experience in two public hospitals. Poster presented at the Annual Meeting of the American Association for Geriatric Psychiatry, Cancun, Mexico, Februar, 1995
23. Aronson SM, Lingam V, Hasanat KA: Risperidone in the treatment of elderly psychiatric patients. Poster presented at the Annual Meeting of the American Association for Geriatric Psychiatry, Tucson, AZ, February, 1996
24. Madhusoodanan S, Brenner R, Araujo L, et al: Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56:11
25. Prado N, Kraemer-Ginsberg E, Kremen N, et al: Risperidone in dementia with behavioral disturbances. Poster presented at the Annual Meeting of the American Psychiatric Association, Miami, FL, May, 1995
26. Borison RL, Davidson M, Berman I: Risperidone treatment in elderly patients with schizophrenia or dementia. Poster presented at the Annual Meeting of the Institute of Hospital and Community Psychiatry, San Diego, CA, October, 1994
27. Goldberg TE, Daniel DG, Pickar D, et al: Differential effects of risperidone and conventional neuroleptics on neurocognition: a pilot study. Poster presented at the Annual Meeting of the American Psychiatric Association, Miami, FL, May, 1995
28. Jeanblanc W, Davis YB: Risperidone for treating dementia-associated aggression. Am J Psychiatry 1995; 152:1239
29. Evans EG Jr: Risperidone in institutionalized psychotic patients unresponsive to conventional antipsychotic agents. Poster presented at the Annual Meeting of the American Psychiatric Association, Miami, FL, May, 1995
30. Jeste DV, Eastham JH, Lacro JP, et al: Management of late-life psychosis. J Clin Psychiatry 1996; 57(suppl 3):39-45
31. Cohen-Mansfield J, Werner P, Marx MS: An observational study of agitation in agitated nursing home residents. Int Psychogeriatr 1989; 1:153-165
32. Weiner MF, Teri L, Williams BT: Psychological and behavioral management, in The Dementias: Diagnosis, Management, and Research, 2nd Edition. Edited by Weiner ME Washington, DC, American Psychiatric Press, 1996, pp 139-173
33. McKhann G, Drachman D, Folstein M, et al: Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944
34. Yudofsky SC, SilverJM, Jackson W, et al: The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143:35-39
35. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
36. Montgomery GK, Reynolds NC, Warren RM: Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985; 8:83-92
37. Barnes TRE: A rating scale for drug-induced akathisia. BrJ Psychiatry 1989; 154:672-676
38. Sultzer DL, Gray KF, Gunay I, et al: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5:60-69
39. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Washington, DC, U.S. Department of Health, Education, and Welfare, 1976
40. Schneider LS: Efficacy of treatment for geropsychiatric illness. Psychopharmacol Bull 1993; 29:501-524
41. Carlyle W, Ancill RJ, Sheldon L: Aggression in the demented patient: a double-blind study of loxapine vs. haloperidol. Int Clin Psychopharmacol 1993; 8:103-108
42. Coccaro EF: Impulsive aggression and central serotonergic system function in humans: an example of a dimensional brain-behavior relationship. Int Clin Psychopharmacol 1992; 7:12-13
43. Greenwald BS, Marin DB, Silverman SM: Serotonergic treatment of screaming and banging in dementia. Lancet 1986; 2:1464-1465
44. Kirby M, Lawlor BA: Biologic markers and neurochemical correlates of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8(suppl 1):S2-S7
45. Elrod R, Peskind ER, DiGiacomo L, et al: Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997; 154:25-30
46. Heykants J, Huang M-L, Mannens G, et al: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(suppl 5):13-17
47. Pollock BG, Mulsant BH, Sweet RA, et al: Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31:327-332
48. Roth GS, Joseph JA: Cellular and molecular mechanisms of impaired dopaminergic function during aging. Ann NY Acad Sci 1994; 719:129-135
49. Brown FB: The neurobiology of late-life psychosis. Crit Rev Neurobiol 1993; 7:275-289
50. Rich SS, Friedman JH, Ott BR: Risperidone vs. clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic/rigid syndromes. J Clin Psychiatry 1995; 56:556-559
51. Ford B, Lynch T, Green P: Risperidone in Parkinson's disease (letter). Lancet 1994; 344:681
52. Sweet RA, Mulsant BH, Pollock BG, et al: Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer's type. Am J Geriatr Psychiatry 1996; 4:311-319
53. King DJ: The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157:799-811
54. King DJ: Psychomotor impairment and cognitive disturbance induced by neuroleptics. Acta Psychiatr Scand 1994; 89(suppl 380):53-58
55. Breggin PR: Parallels between neuroleptic effects and lethargic encephalitis: the production of dyskinesias and cognitive disorders. Brain Cogn 1993; 23:8-27
56. Devanand DP, Sackeim HA, Brown RP, et al: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854-857
57. Lewander T: Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994; 89(suppl 380):8-13